Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • Riluzole
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Riluzole

Therapeutics

Brands

• Rilutek

Generic?

No

Class

• Neuromuscular drug, centrally acting

Commonly Prescribed for

(FDA approved in bold)
• Amyotrophic lateral sclerosis (ALS)

How the Drug Works

• The mode of action is unknown, but the effect in ALS is felt to be from glutamate antagonism. Putative mechanisms include inhibition of glutamate release, interference with transmitter binding at excitatory amino acid receptors, and inactivation of voltage-gated sodium channels. In animal models, appears to be neuroprotective in mice with human superoxide dismutase mutations and has sedative and myorelaxant properties at large doses

How Long Until It Works

• Steady state is reached in 5 days, but it can take months to assess any clinical effect from the drug

If It Works

• ALS is a degenerative disease and deterioration is the general rule. Riluzole can increase survival or time to tracheostomy but is not a cure

If It Doesn't Work

• It is difficult to determine if the treatment is effective, especially because ALS progression varies greatly from patient to patient. Supportive care is the mainstay of current ALS treatment. This may include monitoring and treatment of gait, swallowing and respiratory difficulties

Best Augmenting Combos for Partial Response or Treatment-Resistance

• No other medication is indicated for the treatment of ALS progression

Tests

• Measure serum transaminases, including ALT levels, at baseline and monthly for 3 months. Then evaluate every 3 months for the first year and periodically after that. Once ALT exceeds 5 times normal, begin checking weekly, and discontinue if ALT exceeds 10 times normal or clinical symptoms, such as jaundice, occur
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us